KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2025 value amounting to 0.32%.

  • CRISPR Therapeutics AG's Return on Capital Employed fell 1000.0% to 0.32% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.32%, marking a year-over-year decrease of 1000.0%. This contributed to the annual value of 0.32% for FY2025, which is 1000.0% down from last year.
  • CRISPR Therapeutics AG's Return on Capital Employed amounted to 0.32% in Q4 2025, which was down 1000.0% from 0.28% recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Return on Capital Employed registered a high of 0.19% during Q2 2021, and its lowest value of 0.32% during Q4 2025.
  • In the last 5 years, CRISPR Therapeutics AG's Return on Capital Employed had a median value of 0.22% in 2021 and averaged 0.15%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first soared by 3700bps in 2021, then plummeted by -4500bps in 2022.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Return on Capital Employed stood at 0.14% in 2021, then tumbled by -321bps to 0.31% in 2022, then surged by 65bps to 0.11% in 2023, then plummeted by -99bps to 0.22% in 2024, then plummeted by -46bps to 0.32% in 2025.
  • Its Return on Capital Employed stands at 0.32% for Q4 2025, versus 0.28% for Q3 2025 and 0.28% for Q2 2025.